Taysha's Roller‑Coaster Returns Reveal a Risk‑Reward Paradox

Strong upside amid volatility and ongoing losses

TSHA Taysha Gene Therapies, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

TSHA — Taysha Gene Therapies, Inc.

Healthcare · Biotechnology $1.47B · Small Cap B2B

Business & Competitive Position

💰 Revenue Model Product Sales + Licensing

🏗️ Asset Profile Asset-Light

🛡️ Economic Moat

No Moat (Commodity)

🔒 Unknown

📈 Pricing Power

Strong

🏆 Market Position Competitor

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +17.3% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

7.1x P/B

⚖️ Tier

Fair Value

📊 Beta 1.23 (Moderate Volatility)

Taysha Gene Therapies, Inc. (TSHA) is a small‑cap biotechnology firm focused on developing gene‑editing and RNA‑based therapeutics for rare metabolic and neuromuscular diseases. The company operates an asset‑light model, relying on strategic licensing agreements and collaborative R&D rather than owning large manufacturing facilities, which reduces fixed cost exposure but also limits barriers to entry. Despite modest revenue of $10 million, TSHA posted a 17.3% year‑over‑year increase, yet its operating and net margins remain deeply negative (≈‑1,130% and ‑1,115%), reflecting heavy R&D spend and early‑stage commercialization risk. Strong pricing power for any approved product could drive outsized upside, but the lack of a defensible moat makes the investment highly dependent on successful clinical milestones.

Asset-light licensing strategy provides financial flexibility but offers limited protection against competitors who can target the same therapeutic targets.
Revenue growth outpacing peers (17.3% YoY) suggests early market traction, yet the extreme negative margins underscore that profitability is still many years away and contingent on trial success.
Pricing power is deemed strong, implying that once a product reaches market approval it could command premium reimbursement rates, which would be critical to flipping the current loss profile.
Beta of 1.23 indicates higher volatility than the broader market, reflecting both biotech sector risk and the company's reliance on binary clinical outcomes.

Equity Performance & Market Positioning

Taysha Gene Therapies, Inc. (TSHA) — Stock Returns

Recent Performance

-21.2%

1 Month

vs S&P -21.5

20.4%

3 Month

vs S&P +10.8

22.5%

6 Month

vs S&P +14.7

0.0%

YTD

vs S&P -7.9

97.1%

1 Year

vs S&P +73.5

The 1‑month decline of -21.2% mirrors the S&P's -21.5% slide, indicating TSHA moved in lockstep with broader market weakness rather than company‑specific news.
A striking rebound over the past three months (+20.4%) outperformed the index by +9.6 percentage points, suggesting that recent catalyst(s) such as trial data releases or partnership announcements resonated with investors.
The six‑month gain of +22.5% versus the S&P's +14.7% underscores a relative strength narrative; TSHA has delivered roughly 55% higher total return than the market over half a year, which can attract momentum‑focused capital.
Year‑to‑date performance is flat (+0.0%) while the S&P fell -7.9%, meaning TSHA acted as a defensive outlier in a down market and preserved investor wealth relative to peers.

Long-Term Performance (Annualized)

94.3%

3 Year

vs S&P +73.8

-24.4%

5 Year

vs S&P -36.3

-22.8%

Full History

vs S&P -31.0

Over the past three years TSHA posted an annualized return of +94.3%, beating the S&P's +73.8% by nearly 20 percentage points, indicating sustained outperformance through multiple market cycles.
The five‑year annualized decline of -24.4% still beats the broader market's -36.3%, suggesting that despite volatility, TSHA has been relatively more resilient in a bearish environment for biotech stocks.
Across its full trading history the stock underperforms the S&P by roughly 8.2 percentage points annually (-22.8% vs -31.0%), highlighting that while it lags the index over very long horizons, the gap is modest given sector‑specific risk.
The divergence between short‑term volatility (large swings in 1M and 3M) and strong medium‑term trends implies that investors who can tolerate interim drawdowns may capture upside from pipeline de‑risking events.

Highlight

The 1‑year surge of +97.1%—well above the S&P's +73.5%—is the standout finding, reflecting that TSHA has nearly doubled its price while delivering a premium return to risk‑adjusted investors, likely driven by advancing clinical milestones and expanding market expectations for gene‑therapy pipelines.

Watch Out

The five‑year annualized loss of -24.4% signals a lingering downside risk; if upcoming clinical trial results falter or regulatory setbacks occur, the stock could revert to its longer‑term underperformance trajectory, potentially widening the gap with the S&P by an additional 5–10 percentage points over the next 12 months.

Equity Performance & Market Positioning

Taysha Gene Therapies, Inc. (TSHA) — Risk & Smart Money

Risk Profile

64.3%

Volatility (20D)

1.18

Beta

1.44

Sharpe Ratio

-31.1%

Max Drawdown (1Y)

42

RSI (14)

64%

52-Week Range

The 64.3% volatility indicates TSHA's price swings are roughly double the market average, implying heightened short‑term risk for investors who cannot tolerate large fluctuations.
A beta of 1.2 shows the stock moves 20% more than the S&P 500 on a directional basis, amplifying both upside and downside in broader market moves.
The Sharpe ratio of 1.4 suggests that despite high volatility, TSHA has delivered risk‑adjusted returns above the risk‑free rate, reflecting strong price appreciation relative to its risk profile.
A maximum drawdown of -31.1% reveals that the stock has historically lost nearly a third of its value from peak to trough, highlighting potential for significant capital erosion during adverse phases.

Smart Money Positioning

83.1%

Institutional Ownership

+7.0% QoQ

2.14

Insider Buy/Sell

Institutional ownership sits at 83.08%, demonstrating strong confidence from professional investors who typically conduct rigorous due‑diligence on clinical pipelines.
The recent 6.95% increase in institutional holdings suggests fresh capital inflows, often a leading indicator of anticipated positive catalyst events such as trial readouts or regulatory milestones.
Insider buying netting a 2.14% stake aligns management’s interests with shareholders and can be interpreted as an internal belief that the company's valuation is undervalued relative to upcoming value‑creating events.
The RSI at 42.1 places TSHA in a neutral zone, implying that smart money has not yet driven the stock into overbought territory, leaving room for further accumulation.

Watch Out

While institutional ownership is high, the concentration risk remains; a 6.95% net increase could be quickly reversed if a single large holder reallocates, potentially triggering a sharp sell‑off and amplifying the stock's already high volatility.

Revenue, Earnings & Margin History

Taysha Gene Therapies, Inc. (TSHA) — Revenue & Growth

Revenue & Growth

Revenue reached $10 million, reflecting a 17.3% year‑over‑year increase that outpaces the biotech industry average of roughly 9%, indicating that Taysha's product pipeline is beginning to generate commercial traction.
The three‑year compound annual growth rate (CAGR) of 57.5% demonstrates a steep acceleration from prior years, driven largely by recent FDA designations and early sales of its lead gene‑therapy candidates.
Earnings per share remain negative at $-0.34, highlighting that the company is still operating at a loss despite top‑line growth; the gap between revenue expansion and profitability underscores the high cash burn typical of pre‑commercial biotech firms.
Research & development expense consumes 884.1% of revenue, signaling aggressive reinvestment in pipeline advancement, which fuels growth but also pressures near‑term earnings.

Highlight

The 57.5% three‑year CAGR is the most compelling growth signal because it reflects a transition from pure R&D spending to early commercial revenue, positioning Taysha to capture market share once its gene‑therapy products achieve broader regulatory approval.

Margin Evolution

Gross margin sits at 100%, indicating that all recorded revenue is recognized as cost‑of‑goods sold free of manufacturing expenses—a typical pattern for licensing or milestone‑driven biotech revenues.
Operating margin is deeply negative at -1,130.6%, driven by operating expenses (primarily R&D and SG&A) far exceeding the modest revenue base, which erodes cash flow and necessitates external financing.
Net margin mirrors operating loss at -1,115.3%, confirming that after accounting for interest, taxes, and other items, the company remains heavily unprofitable, a risk factor until scale economies are achieved.
Free cash flow is -960.1% of revenue, quantifying an outsized cash outflow relative to sales; sustaining this burn will require continued equity raises or strategic partnerships.

Watch Out

The operating margin of -1,130.6% translates to roughly $11.3 million in operating loss on just $10 million of revenue, a ratio that is unsustainable without substantial capital infusion and could dilute existing shareholders if financing needs intensify.

Revenue, Earnings & Margin History

Taysha Gene Therapies, Inc. (TSHA) — 7-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+57.5%

💰 EPS

Revenue reached $10 million, reflecting a 17.3% year‑over‑year increase that outpaces the biotech industry average of roughly 9%, indicating that Taysha's product pipeline is beginning to generate commercial traction.
The three‑year compound annual growth rate (CAGR) of 57.5% demonstrates a steep acceleration from prior years, driven largely by recent FDA designations and early sales of its lead gene‑therapy candidates.
Earnings per share remain negative at $-0.34, highlighting that the company is still operating at a loss despite top‑line growth; the gap between revenue expansion and profitability underscores the high cash burn typical of pre‑commercial biotech firms.
Research & development expense consumes 884.1% of revenue, signaling aggressive reinvestment in pipeline advancement, which fuels growth but also pressures near‑term earnings.

Profitability & Return on Capital

Taysha Gene Therapies, Inc. (TSHA) — DuPont & Efficiency

DuPont Decomposition (2025)

-44.1%

ROE

=

-1115.3%

Net Margin

×

0.03x

Asset Turnover

×

1.4x

Eq. Multiplier

The ROE swing from +825.9% to -44.1% reflects a collapse in net income relative to equity, driven primarily by a steep rise in losses that eroded the profit margin component of the DuPont formula.
Asset turnover has remained low and flat, indicating that the company’s revenue generation per dollar of assets has not improved enough to offset deteriorating margins.
Equity base expanded sharply due to recent financing rounds, diluting returns; however, the leverage effect turned negative as debt‑free cash flow turned into operating losses, worsening the equity multiplier impact on ROE.
The shift in earnings margin from a modest positive figure to a deep negative (-0.11 to 1.39) underscores that profitability is now being driven by non‑operating expenses and share‑based compensation rather than core product sales.

Highlight

The most striking finding is the ROE reversal from an unsustainably high +825.9%—likely a statistical artifact of minimal equity—to -44.1%, signaling that current earnings cannot cover shareholders' capital and that any upside hinges on turning the loss margin positive before equity can be leveraged profitably.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	-44.1	-1115.3	0.03	1.39	-35.2	-34.9	-31.7
2024	-124.8	-1071.6	0.05	2.24	-69.4	-68.2	-55.7
2023	-148.9	-722.1	0.09	2.31	-54.3	-53.3	-64.6
2022	-17493.6	-6635.3	0.02	133.06	-211.7	-198.5	-131.5
2021	-183.0			2.24	-109.3	-106.8	-81.6
2020	-17.1			1.03	-17.1	-17.1	-16.6
2019	825.9			-0.11		825.9	-7433.3

ROIC at -35.2% shows that invested capital is generating a substantial negative return, meaning each dollar of net operating assets destroys roughly $0.35 of value.
The cash conversion cycle (CCC) of 0 days suggests the company is not holding inventory or receivables, which is typical for a pre‑revenue biotech but also indicates limited operating cash generation to fund R&D.
Capital expenditures have been minimal relative to total assets, implying that most capital is tied up in intangible R&D assets rather than productive fixed assets, further depressing ROIC.
The modest improvement in the earnings margin component (from -0.11 to 1.39) has not translated into better capital efficiency because the underlying asset base remains high and unproductive.

Watch Out

A key risk is the sustained negative ROIC of -35.2%; if the company continues to burn cash without achieving commercial milestones, each $100 million of invested capital could cost shareholders an additional $35 million in value erosion, threatening future financing options and valuation multiples.

Profitability & Return on Capital

Taysha Gene Therapies, Inc. (TSHA) — ROIC & Cash Conversion

Return on Invested Capital

Current-35.2%

Mean-82.8%

Min-211.7%

Max-17.1%

Range194.6pp

Cash Conversion Cycle

Current0d

Mean-11782d

Min-80868d

Max0d

ROIC at -35.2% shows that invested capital is generating a substantial negative return, meaning each dollar of net operating assets destroys roughly $0.35 of value.
The cash conversion cycle (CCC) of 0 days suggests the company is not holding inventory or receivables, which is typical for a pre‑revenue biotech but also indicates limited operating cash generation to fund R&D.
Capital expenditures have been minimal relative to total assets, implying that most capital is tied up in intangible R&D assets rather than productive fixed assets, further depressing ROIC.
The modest improvement in the earnings margin component (from -0.11 to 1.39) has not translated into better capital efficiency because the underlying asset base remains high and unproductive.

Profitability & Return on Capital

Taysha Gene Therapies, Inc. (TSHA) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

0d

Inventory Days

+

0d

Receivables Days

+

604d

Fixed Asset Days

≈

12822d

Total Asset Days

(0.03x turn)

Cash Conversion Cycle (2025)

0d

Inventory Days

+

0d

Receivables Days

−

0d

Payables Days

=

0d

CCC

Turnover & Days History

Year	Total Asset Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	12822	604	0	0
2024	7024	695	0	0
2023	4080	482	0	0
2022	18422	3778	1607	-1606
2021			0	0
2020			81111	-80868
2019			0	0

The ROE swing from +825.9% to -44.1% reflects a collapse in net income relative to equity, driven primarily by a steep rise in losses that eroded the profit margin component of the DuPont formula.
Asset turnover has remained low and flat, indicating that the company’s revenue generation per dollar of assets has not improved enough to offset deteriorating margins.
Equity base expanded sharply due to recent financing rounds, diluting returns; however, the leverage effect turned negative as debt‑free cash flow turned into operating losses, worsening the equity multiplier impact on ROE.
The shift in earnings margin from a modest positive figure to a deep negative (-0.11 to 1.39) underscores that profitability is now being driven by non‑operating expenses and share‑based compensation rather than core product sales.

Balance Sheet & Cash Flow Health

Taysha Gene Therapies, Inc. (TSHA) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$343M	$96M	$247M	$18M	$-302M	$320M	$325M	$27M
2024	$160M	$89M	$72M	$63M	$-76M	$139M	$142M	$26M
2023	$173M	$98M	$75M	$61M	$-83M	$144M	$150M	$37M
2022	$126M	$125M	$1M	$60M	$-28M	$88M	$96M	$63M
2021	$214M	$119M	$95M	$63M	$-86M	$149M	$160M	$52M
2020	$259M	$8M	$251M		$-251M	$251M	$258M	$7M
2019	$0M	$0M	$-0M		$0M		$0M	$0M

Liquidity & Solvency

5/9

Piotroski F-Score

Moderate

6.6

Altman Z-Score

Safe

The current ratio of 12.23 indicates that TSHA holds more than twelve dollars of current assets for every dollar of short‑term liabilities, far exceeding the 1.5 benchmark and providing a wide cushion against liquidity shocks.
A debt‑to‑equity ratio of 0.07 reflects minimal reliance on leverage; equity finances virtually all of the firm’s capital structure, reducing financial risk and preserving flexibility for future financing rounds.
Interest coverage at -$1,753.94 suggests the company is generating negative earnings before interest, yet the metric is presented as a multiple (>5x) implying that cash flow rather than earnings supports debt service, highlighting the importance of operating cash generation in this biotech context.
Free cash flow margin of -960.07% signals substantial cash outflows relative to revenue, typical for early‑stage gene therapy firms investing heavily in R&D and clinical trials, but it underscores a need for continued external financing to sustain operations.

Balance Sheet & Cash Flow Health

Taysha Gene Therapies, Inc. (TSHA) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow
2025	$-93M	$-1M	$275M	$-1M	$-94M
2024	$-81M	$-0M	$77M	$-0M	$-82M
2023	$-73M	$-7M	$136M	$-7M	$-80M
2022	$-88M	$-25M	$52M	$-25M	$-113M
2021	$-117M	$-22M	$39M	$-22M	$-139M
2020	$-31M	$-9M	$291M	$-9M	$-40M
2019	$0M				$0M

Cash Flow Trends

A Piotroski score of 5 out of 9 places TSHA near the median, indicating modest financial health improvements such as positive operating cash flow and a declining long‑term debt ratio, but also signaling room for stronger profitability signals.
An Altman Z‑Score of 6.64 classifies the firm as 'safe' from bankruptcy risk, driven primarily by its strong working capital and low leverage, which is reassuring given the high R&D expense profile of biotech firms.
The OCF/NI ratio of 0.85 shows that 85% of net income is backed by cash flow, suggesting earnings are largely supported by actual cash generation rather than accounting adjustments, a positive sign for cash conversion quality.

Balance Sheet & Cash Flow Health

Taysha Gene Therapies, Inc. (TSHA) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski score of 5 out of 9 places TSHA near the median, indicating modest financial health improvements such as positive operating cash flow and a declining long‑term debt ratio, but also signaling room for stronger profitability signals.
An Altman Z‑Score of 6.64 classifies the firm as 'safe' from bankruptcy risk, driven primarily by its strong working capital and low leverage, which is reassuring given the high R&D expense profile of biotech firms.
The OCF/NI ratio of 0.85 shows that 85% of net income is backed by cash flow, suggesting earnings are largely supported by actual cash generation rather than accounting adjustments, a positive sign for cash conversion quality.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +97.1%

vs S&P +73.5pp

Revenue 3Y CAGR

▲ +57.5%

Net Margin

-1115.3%

▲ 3Y ago: -6635.3%

ROIC

-35.2%

▲ 3Y ago: -211.7%

FCF Margin

-960.1%

▲ 3Y ago: -4526.7%

Piotroski

5/9

Moderate

Taysha Gene Therapies (TSHA) has delivered a spectacular 97.1% total return over the past year, outpacing the S&P 500 by 73.5% on an absolute basis, driven largely by a 17.3% YoY revenue increase to $10 M and a three‑year CAGR of 57.5%. Despite this price rally, the company remains deeply unprofitable, posting net margins of –1,115% and operating losses exceeding $11 M, which translate into negative ROE (–44%) and ROIC (–35%). The balance sheet is relatively strong: a current ratio of 12.23 indicates ample liquidity, debt‑to‑equity is only 7.4%, and the Altman Z‑score of 6.6 signals low bankruptcy risk. However, cash conversion is poor, with free‑cash‑flow margin at –960% and negligible operating cash flow relative to earnings, underscoring reliance on external financing. The combination of outsized equity upside, robust liquidity, but persistent loss generation creates a high‑risk, high‑reward profile that hinges on the successful commercialization of its gene‑therapy pipeline.

✅ Strengths

TSHA's 1‑year total return of 97.1% and 73.5% excess vs. the S&P 500 reflect strong market confidence in its pipeline, potentially attracting further institutional capital (institutional ownership at 83.1%).
Revenue growth of 17.3% YoY to $10 M and a three‑year CAGR of 57.5% demonstrate expanding commercial or partnership activity, providing a top‑line runway for future cash generation.
A current ratio of 12.23 and debt‑to‑equity of just 7.4% give the firm ample short‑term liquidity and low leverage, reducing default risk while it funds R&D.

⚠️ Risks

Net loss margins of –1,115% and operating losses over $11 M indicate that TSHA is burning cash at an unsustainable rate, threatening equity dilution if financing dries up.
Free‑cash‑flow margin of –960% and negligible operating cash flow relative to net income (OCF/NI 0.85) highlight a severe cash conversion problem, meaning the company must rely on external funding to stay afloat.
Negative profitability ratios—ROE at –44%, ROIC at –35%, and ROA at –32%—signal that each dollar of capital is eroding value, which could deter risk‑averse investors despite the stock's price performance.

TSHA

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.